Press Releases and Blog
Blog
ICYMI: RealClearHealth: Pat Toomey: Attacking PBMs Won’t Solve President Biden’s Inflation Problem
In case you missed it, former U.S. Senator Pat Toomey (R-PA) explains how the Biden Administration’s recent push targeting pharmacy benefit companies is a deflecting
ICYMI: Ike Brannon: Recently Proposed Federal And State Legislation To Constrain Pharmacy Benefit Managers Would Not Reduce Drug Costs
In case you missed it, Ike Brannon, health care economist and senior fellow at the Jack Kemp Foundation, published a new white paper, “Recently Proposed
Misguided Proposals Targeting Pharmacy Benefit Companies Would Increase Prescription Drug Costs for Patients, Take Away Options From Health Plan Sponsors, Like Employers and Unions
Proponents of policies targeting pharmacy benefit companies ignore the costly repercussions of undermining pharmacy benefit managers’ (PBMs) ability to secure savings that enable health plan
Renewed Congressional Focus On Patent Abuse Touts Proposals to Effectively Lower Prescription Drug Costs, Strengthen Competition in the Market
U.S. Senators Peter Welch (D-VT), Mike Braun (R-IN), and Amy Klobuchar (D-MN) recently introduced legislation that will crack down on drug companies’ patent abuse, specifically patent
ICYMI: 2021 House Oversight Committee Report Concluded Rebates Are Uncorrelated With Drug Prices
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with
ICYMI: Former U.S. Senator Pat Toomey: GOP Can’t Afford to Start 2024 with Giant Health Care Mandates
In case you missed it, former U.S. Senator Pat Toomey (R-PA) warns Republican policymakers against passing unvetted and disastrous policies targeting pharmacy benefits being debated
Press Releases
PCMA Releases Statement on Kentucky House Bill 220
(Frankfort, KY) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the passage of House Bill 220 in Kentucky. “PCMA applauds the
PCMA Releases Statement On White House PBM Listening Session
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the Administration’s listening session on PBMs. “Today’s White House listening session
PCMA Urges HELP Committee Lawmakers To Reject False Blame Game, Hold Drug Companies Accountable For Anti-Competitive Practices
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement ahead of a U.S. Senate Committee on Health, Education, Labor, and Pensions
Waltz Health Joins Pharmaceutical Care Management Association
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today announced that Waltz Health is joining the trade association as its newest member. “PCMA is
PCMA Supports Bill to Address Big Pharma’s Patent Thickets
New Bipartisan Legislation would Crack Down on Routine Abuse of the Drug Patent System to Keep More Affordable Alternatives Off Market (Washington, D.C.) — The
PCMA Report Details Increased Costs Associated with Legal Changes in Tennessee
Ever-Broadening Actions Will Increase Prescription Drug Spending by Nearly $5 Billion (Nashville, TN) — The Pharmaceutical Care Management Association (PCMA) today released a report finding that recent
ICYMI: RealClearHealth: Pat Toomey: Attacking PBMs Won’t Solve President Biden’s Inflation Problem
In case you missed it, former U.S. Senator Pat Toomey (R-PA) explains how the Biden Administration’s recent push targeting pharmacy benefit companies is a deflecting
ICYMI: Ike Brannon: Recently Proposed Federal And State Legislation To Constrain Pharmacy Benefit Managers Would Not Reduce Drug Costs
In case you missed it, Ike Brannon, health care economist and senior fellow at the Jack Kemp Foundation, published a new white paper, “Recently Proposed
Misguided Proposals Targeting Pharmacy Benefit Companies Would Increase Prescription Drug Costs for Patients, Take Away Options From Health Plan Sponsors, Like Employers and Unions
Proponents of policies targeting pharmacy benefit companies ignore the costly repercussions of undermining pharmacy benefit managers’ (PBMs) ability to secure savings that enable health plan
Renewed Congressional Focus On Patent Abuse Touts Proposals to Effectively Lower Prescription Drug Costs, Strengthen Competition in the Market
U.S. Senators Peter Welch (D-VT), Mike Braun (R-IN), and Amy Klobuchar (D-MN) recently introduced legislation that will crack down on drug companies’ patent abuse, specifically patent
ICYMI: 2021 House Oversight Committee Report Concluded Rebates Are Uncorrelated With Drug Prices
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with
ICYMI: Former U.S. Senator Pat Toomey: GOP Can’t Afford to Start 2024 with Giant Health Care Mandates
In case you missed it, former U.S. Senator Pat Toomey (R-PA) warns Republican policymakers against passing unvetted and disastrous policies targeting pharmacy benefits being debated
ICYMI: New Report Underscores That Rebates Have No Correlation With High Drug Prices
In case you missed it, a new report from health policy researcher Alex Brill, founder and CEO of Matrix Global Advisors and former policy director
ICYMI: New Public Employee Policy Research Affirms PBMs Are Essential In Administering Pharmacy Benefits, Public Sector Employers Satisfied With Their Pharmacy Benefit Companies
In case you missed it, the National Institute for Public Employee Health Care Policy recently released a report, “How Public Sector Health Care Purchasers Are
ICYMI: Former Senator Pat Toomey Cautions Congress Against Proposals Targeting Pharmacy Benefit Companies
In case you missed it, WTOP’s Mitchell Miller spoke with former U.S. Senator Pat Toomey (R-PA) about the current health care debate in Congress in
ICYMI: Former Representative Altmire Joins Former U.S. Senator Pat Toomey In Cautioning Lawmakers Against Passing Proposals Targeting Pharmacy Benefits
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called